BELGRADE, Serbia, May 18 /PRNewswire-FirstCall/ - Hard to Treat
Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com is pleased to
announce the second poster presentation researchers from its
Slavica BioChem (www.slavicabiochem.com) division have presented at
the 8th World Congress on the Brain Injury, held in Washington, DC, March
10-14, 2010, under the auspices of The International Brain
Injury Association (IBIA) http://www.internationalbrain.org/. The
Slavica team presented results which show the potential beneficial
effects of repetitive treatment with the cocktail of B vitamins
(B1, B2, B3, B6, and B12) on recovery after traumatic brain injury.
The IBIA World Congress is the largest gathering of international
professionals working in the field of brain injury. Experts of
different background took part in this Congress: scientists,
physicians, psychologists and neuropsychologists, therapists,
social workers, nurses and other professionals involved in the
field of brain injury. The Organizers reported the 2010 Meeting was
the largest IBIA meeting ever organized, with more than 1000
participants and over 650 accepted abstracts.
Prof Mirjana Stojiljkovic, the
leader of Slavica BioChem research team said: "As Dr Pekovic in
previous press release (April 6,
2010) mentioned this Congress was an excellent opportunity
to get insight into the state-of-the-art research, from the basic
science to the clinical aspects of brain injury, as well as for
establishing important contacts with international professionals
involved in the brain injury research and the care of people with
acquired brain injury. At the same time, we were able to present
our results in a summary Poster format which was available for
review by attendees. We had 3h long session with the visitors of
our poster presentation discussing all the questions on the topic
presented. Since our results belong to the basic science and are
focused to cellular mechanisms underlying traumatic brain injury
(TBI) they were very attractive for the numerous medical doctors
attending the Congress. Namely, despite all efforts TBI continues
to pose a significant health care risk for which there is currently
no effective treatment. For many years we are looking for the
approaches that could improve recovery after TBI. In this study we
focused our attention to B vitamins."
Prof. Mirjana Stojiljkovic added:
"Most importantly, the results of our behavioral studies indicated
that repetitive treatment with the cocktail of B vitamins (B1, B2,
B3, B6, and B12), significantly improved motor coordination of
movement. Looking for the effects at the cellular level we observed
that B vitamins could induce reduction of glial scar that has been
considered as one of the major impediments to neuronal
regeneration."
In summary, Prof. Mirjana
Stojiljkovic concluded: "These findings are encouraging,
they expand and further validate the use of B vitamins as a
potentially effective treatment that should be seriously considered
for clinical trials in TBI."
For any matters relating to retail investor queries or to send
the company or its IR a message please click on the "INVESTOR
SUPPORT" TAB, or the direct link
http://www.minamargroup.net/helpdesk.
Don't be a victim. Report a stock basher. The company is mindful
that short sellers, the company competitors and stock bashers stalk
small cap Pink Sheets listed companies with hidden agendas. Visit
http://www.stockbasher.com/ and find out what criminal and civil
actions the US authorities are taking against web sites like
investorshub.com and other posters, and the remedies available to
you as an individual investor.
Filings for this event are currently being reviewed and will be
filed with Pink Sheets and Client Support section in due course. To
be included in company's email database for press releases,
industry updates, and non-weekly activity in the company that may
or may not be news released, please subscribe or opt in mailer at
http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future
expectations, plans, prospects or performance of Hard to Treat
Diseases, Inc. that constitute forward-looking statements for
purposes of the safe harbor Provisions under the Private Securities
Litigation Reform Act of 1995. The words or phrases "can be,"
"expects," "may affect," "believed," "estimate," "project," and
similar words and phrases are intended to identify such
forward-looking statements. HTDS Corporation cautions you that any
forward-looking information provided by or on behalf of Hard to
Treat Diseases, Inc. is not a guarantee of future performance. None
of the information in this filing constitutes or is intended as an
offer to sell securities or investment advice of any kind. Hard to
Treat Diseases, Inc.'s actual results may differ materially from
those anticipated in such forward-looking statements as a result of
various important factors, some of which are beyond Hard to Treat
Diseases, Inc.'s control. In addition to those discussed in Hard to
Treat Diseases, Inc.'s press releases, public filings, and
statements by Hard to Treat Diseases, Inc.'s management, including,
but not limited to, Hard to Treat Diseases, Inc.'s estimate of the
sufficiency of its existing capital resources, Hard to Treat
Diseases, Inc.'s ability to raise additional capital to fund future
operations, HTDS Corporation's ability to repay its existing
indebtedness, the uncertainties involved in estimating market
opportunities and, in identifying contracts which match Hard to
Treat Diseases, Inc.'s capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which
such statements were made. Hard to Treat Diseases, Inc. does not
undertake any obligation to publicly update any forward-looking
statement to reflect events or circumstances after the date on
which any such statement is made or to reflect the occurrence of
unanticipated events.
CONTACT: www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases